Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

Clinical Activity of Icotinib in Patients With Advanced Non-small-cell Lung Cancer Harbouring Uncommon EGFR Mutations: a Single-arm, Prospective, Phase 2 Study

This study aims to evaluate the efficacy of icotinib, a first generation EGFR TKI, in non-small cell lung cancer patients harboring uncommon EGFR mutation

Inclusion Criteria:

• Patients with stage IIIB/IV non-small cell lung cancer
• Patients with uncommon epidermal growth factor receptor (EGFR) mutation
• Targeted-therapy-naive patients
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
• Evaluable target lesions according to RECIST 1.1 for tumour response assessment

Exclusion Criteria:

• Wild-type EGFR
• Positive 19 del and/or 21 L858R mutation
• Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib
• Patients who have documented history of interstitial lung disease